New treatment for glaucoma using nerve growth factor and vitamin B3
Topical NGF Therapy and oral nicotinamide supplementation for Glaucoma
This study is testing a new treatment for glaucoma that combines eye drops with a vitamin supplement to help protect and improve the health of eye cells, especially for people who haven't had success with current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Human Cell Co NIH-funded |
| Lab location | 1 site (Naperville, United States) |
| Project ID | NIH-11004461 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for glaucoma that combines topical nerve growth factor (NGF) treatment with oral nicotinamide supplementation. Glaucoma leads to the degeneration of retinal ganglion cells, causing irreversible vision loss, and current treatments primarily focus on lowering intraocular pressure. The study aims to protect these cells from degeneration and enhance their function, potentially offering a new approach for patients who do not respond to existing therapies. The research utilizes animal models to evaluate the effectiveness of the NGF mutein HC201, which has shown promising results in preserving retinal cell health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glaucoma, particularly those who have not responded adequately to traditional intraocular pressure-lowering treatments.
Not a fit: Patients with glaucoma who are already experiencing advanced vision loss or those who do not have a diagnosis of glaucoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for glaucoma patients, potentially preserving vision and improving quality of life.
How similar studies have performed: Previous research has shown success with similar approaches using nerve growth factor in animal models, indicating potential for effective treatment in humans.
Where this research is happening
Naperville, United States
- Human Cell Co — Naperville, United States (Active)
Researchers
- Principal investigator: Jeong, Soon Seog — Human Cell Co
- Study coordinator: Jeong, Soon Seog
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.